PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

(2021) Chunmeng Wang et al.   Journal of Hematology & Oncology

Immune Microenvironment Change and Involvement of Circular RNAs in TIL Cells of Recurrent Nasopharyngeal Carcinoma

(2021) Yumin Wang et al.   Frontiers in Cell and Developmental Biology

Expression of programmed cell death ligand‑1 protein in germinal center B‑cell‑like and non‑germinal center B‑cell‑like subtypes of diffuse large B‑cell lymphoma

(2021) Rizka Asrini et al.   Molecular and Clinical Oncology

Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab

(2020) Fumiya Wada et al.   ANNALS OF HEMATOLOGY

PD‐L1 expression on tumor or stromal cells of nodal cytotoxic T‐cell lymphoma: A clinicopathological study of 50 cases

(2020) Daisuke Yamashita et al.   PATHOLOGY INTERNATIONAL

Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies

(2020) Sergi Benavente et al.   Frontiers in Oncology

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype

(2019) James Godfrey et al.   BLOOD

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma

(2019) Sixia Huang et al.   Cancer Medicine

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

(2019) Justin Kline et al.   BLOOD

Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma

(2018) Naoko Asano et al.   HISTOPATHOLOGY

Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma

(2018) Jun Zhang et al.   Frontiers in Oncology

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

(2017) Tomas Jelinek et al.   IMMUNOLOGY

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma

(2016) H. Miyoshi et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

(2015) Dohee Kwon et al.   HISTOPATHOLOGY

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies

(2015) David W. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas

(2013) S. Muenst et al.   DISEASE MARKERS

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

(2012) J. Predina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Distribution of PD-1+ Lymphocytes in Reactive Lymphadenopathies

(2010) Simone Muenst et al.   PATHOBIOLOGY

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma

(2009) Joaquim Carreras et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

(2008) B. Chetaille et al.   BLOOD

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

(2008) A. Tzankov et al.   HAEMATOLOGICA